Statin therapy tied to lower long-term mortality in patients with ventricular tachyarrhythmias

  • Rusnak J & al.
  • Lipids Health Dis
  • 24 May 2019

  • curated by Sarfaroj Khan
  • UK Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Statin therapy is independently associated with a reduced risk for long-term all-cause mortality in patients presenting with ventricular tachyarrhythmias on admission.

Why this matters

  • At present, limited data exist regarding the outcomes of patients with statin therapy presenting with ventricular tachyarrhythmias.

Study design

  • This retrospective study included 424 propensity-matched patients admitted with ventricular tachyarrhythmias.
  • Impact of statin therapy on survival was evaluated.
  • Primary endpoint: all-cause death at 3 years.
  • Funding: None.

Key results

  • Majority of patients presented with ventricular tachycardia (VT) vs ventricular fibrillation (VF) with equally distributed rates in statin and non-statin groups (VT: 71% vs 68%; VF: 29% vs 32%).
  • At long-term follow-up (median, 3 years), patients on statin therapy had significantly better survival vs patients on non-statin (mortality rates, 16% vs 33%; log rank P=.001; HR, 0.438; 95% CI, 0.290-0.663; P=.001).
  • The prognostic benefit of statin therapy was irrespective of presence of VT (mortality rates, 15% vs 33%; log rank P=.001; HR, 0.439; 95% CI, 0.267-0.723; P=.001) or VF (mortality rates, 16% vs 34%; log rank P=.028; HR, 0.445; 95% CI, 0.212-0.935; P=.032).
  • The prognostic benefit of statin therapy was evident when stratifying according to left ventricular ejection fraction >35%, presence of an activated implantable cardioverter defibrillator (ICD), cardiogenic shock or cardiopulmonary resuscitation.

Limitations

  • Retrospective design.